Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study

ABSTRACT This study aimed to explore the effect of cyclosporine (CsA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in systemic lupus erythematosus (SLE) patients to provide a valuable reference for clinical treatment strategies in the context of the long-term risk of SAR...

Descripció completa

Dades bibliogràfiques

Autors principals:	He-Jun Li, Shu-Huan Lin, Yan-Qing Wang, Ling Chen, Xiang-Xiong Zheng, Li-Xin Wei
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology 2024-11-01
Col·lecció:	Microbiology Spectrum
Matèries:	systemic lupus erythematosus cyclosporine immunosuppressive therapy SARS-CoV-2 COVID-19
Accés en línia:	https://journals.asm.org/doi/10.1128/spectrum.01276-24
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!